A bispecific nanosystem activates endogenous natural killer cells in the bone marrow for haematologic malignancies therapy
Source abstract
Abstract
Haematologic malignancies commonly arise from the bone marrow lesion, yet there are currently no effective targeted therapies against tumour cells in this location. Here we constructed a bone-marrow-targeting nanosystem, CSF@E-Hn, which is based on haematopoietic-stem-cell-derived nanovesicles adorned with gripper ligands (aPD-L1 and aNKG2D) and encapsulated with colony-stimulating factor (CSF) for the treatment of haematologic malignancies. CSF@E-Hn targets the bone marrow and, thanks to the gripper ligands, pulls together tumour cells and natural killer cells, activating the latter for specific tumour cell targeting and elimination. The therapeutic efficacy was validated in mice bearing acute myeloid leukaemia and multiple myeloma. The comprehensive assessment of the post-treatment bone marrow microenvironment revealed that the integration of CSF into a bone-marrow-targeted nanosystem promoted haematopoietic stem cell differentiation, boosted memory T cell generation and maintained bone homoeostasis, with long-term prevention of relapse. Our nanosystem represents a promising strategy for the treatment of haematologic malignancies.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Immune Cell Function and Interaction · Immunotherapy and Immune Responses · Hematopoietic Stem Cell Transplantation
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (57)
Show source-provided references
1. Craddock, C. & Friedberg, J. W. Immunotherapy for hematologic malignancies. J. Clin. Oncol. 39, 343–345 (2021).10.1200/JCO.20.03106 ↗
2. Noh, J. Y., Seo, H., Lee, J. & Jung, H. Immunotherapy in hematologic malignancies: emerging therapies and novel approaches. Int. J. Mol. Sci. 21, 8000 (2020).10.3390/ijms21218000 ↗
3. Sorror, M. L. et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 106, 2912–2919 (2005).10.1182/blood-2005-05-2004 ↗
4. Schlenk, R. F. Acute myeloid leukemia: introduction to a series highlighting progress and ongoing challenges. Haematologica 108, 306–307 (2023).10.3324/haematol.2022.280803 ↗
5. Harousseau, J. L., Dreyling, M. & ESMO Guidelines Working Group Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 21, 155–157 (2010).10.1093/annonc/mdq178 ↗
6. Mailankody, S. et al. Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS). Blood 118, 4086–4092 (2011).10.1182/blood-2011-05-355743 ↗
7. Petrich, A. M. et al. Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis. Blood 124, 2354–2361 (2014).10.1182/blood-2014-05-578963 ↗
8. Paczesny, S., Pavletic, S. Z. & Bollard, C. M. Introduction to a review series on emerging immunotherapies for hematologic diseases. Blood 131, 2617–2620 (2018).10.1182/blood-2018-04-840793 ↗
9. Cathcart, K. et al. A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia. Blood 103, 1037–1042 (2004).10.1182/blood-2003-03-0954 ↗
10. Ye, Q., Lin, Y., Li, R., Wang, H. & Dong, C. Recent advances of nanodrug delivery system in the treatment of hematologic malignancies. Semin Cancer Biol. 86, 607–623 (2022).10.1016/j.semcancer.2022.03.016 ↗
11. Panagi, M. et al. Polymeric micelles effectively reprogram the tumor microenvironment to potentiate nano-immunotherapy in mouse breast cancer models. Nat. Commun. 13, 7165 (2022).10.1038/s41467-022-34744-1 ↗
12. Montserrat-Vazquez, S. et al. Transplanting rejuvenated blood stem cells extends lifespan of aged immunocompromised mice. NPJ Regen. Med 7, 78 (2022).10.1038/s41536-022-00275-y ↗
13. Li, D. et al. VCAM-1+ macrophages guide the homing of HSPCs to a vascular niche. Nature 564, 119–124 (2018).10.1038/s41586-018-0709-7 ↗
14. Tamplin, O. J. et al. Hematopoietic stem cell arrival triggers dynamic remodeling of the perivascular niche. Cell 160, 241–252 (2015).10.1016/j.cell.2014.12.032 ↗
15. Susek, K. H. et al. Bone marrow laminins influence hematopoietic stem and progenitor cell cycling and homing to the bone marrow. Matrix Biol. 67, 47–62 (2018).10.1016/j.matbio.2018.01.007 ↗
16. Neal, M. L. et al. The glycoprotein GPNMB attenuates astrocyte inflammatory responses through the CD44 receptor. J. Neuroinflammation 15, 73 (2018).
17. Felker, S. et al. Differential CXCR4 expression on hematopoietic progenitor cells versus stem cells directs homing and engraftment. JCI Insight 7, e151847 (2022).10.1172/jci.insight.151847 ↗
18. Fuhrmann, G., Herrmann, I. K. & Stevens, M. M. Cell-derived vesicles for drug therapy and diagnostics: opportunities and challenges. Nano Today 10, 397–409 (2015).10.1016/j.nantod.2015.04.004 ↗
19. Tian, T. et al. Surface functionalized exosomes as targeted drug delivery vehicles for cerebral ischemia therapy. Biomaterials 150, 137–149 (2018).10.1016/j.biomaterials.2017.10.012 ↗
20. Rai, A. et al. Proteomic dissection of large extracellular vesicle surfaceome unravels interactive surface platform. J. Extracell. Vesicles 10, e12164 (2021).
21. Woan, K. V. et al. Harnessing features of adaptive NK cells to generate iPSC-derived NK cells for enhanced immunotherapy. Cell Stem Cell 28, 2062–2075.e5 (2021).10.1016/j.stem.2021.08.013 ↗
22. Huntington, N. D., Cursons, J. & Rautela, J. The cancer-natural killer cell immunity cycle. Nat. Rev. Cancer 20, 437–454 (2020).10.1038/s41568-020-0272-z ↗
23. Nakamura, T. et al. STING agonist loaded lipid nanoparticles overcome anti-PD-1 resistance in melanoma lung metastasis via NK cell activation. J. Immunother. Cancer 9, e002852 (2021).10.1136/jitc-2021-002852 ↗
24. Chiossone, L., Dumas, P. Y., Vienne, M. & Vivier, E. Natural killer cells and other innate lymphoid cells in cancer. Nat. Rev. Immunol. 18, 671–688 (2018).10.1038/s41577-018-0061-z ↗
25. Myers, J. A. & Miller, J. S. Exploring the NK cell platform for cancer immunotherapy. Nat. Rev. Clin. Oncol. 18, 85–100 (2021).10.1038/s41571-020-0426-7 ↗
26. Paolino, M. et al. The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells. Nature 507, 508–512 (2014).10.1038/nature12998 ↗
27. Cheng, M., Chen, Y., Xiao, W., Sun, R. & Tian, Z. NK cell-based immunotherapy for malignant diseases. Cell Mol. Immunol. 10, 230–252 (2013).10.1038/cmi.2013.10 ↗
28. Zhang, C. et al. Bispecific antibody-mediated redirection of NKG2D-CAR natural killer cells facilitates dual targeting and enhances antitumor activity. J. Immunother. Cancer 9, e002980 (2021).10.1136/jitc-2021-002980 ↗
29. Parihar, R. et al. NK cells expressing a chimeric activating receptor eliminate MDSCs and rescue impaired CAR-T cell activity against solid tumors. Cancer Immunol. Res 7, 363–375 (2019).10.1158/2326-6066.CIR-18-0572 ↗
30. Luis, T. C. et al. Perivascular niche cells sense thrombocytopenia and activate hematopoietic stem cells in an IL-1 dependent manner. Nat. Commun. 14, 6062 (2023).
31. Duarte, D. et al. Inhibition of endosteal vascular niche remodeling rescues hematopoietic stem cell loss in AML. Cell Stem Cell 22, 64–77.e6 (2018).10.1016/j.stem.2017.11.006 ↗
32. Hiasa, M. et al. GM-CSF and IL-4 induce dendritic cell differentiation and disrupt osteoclastogenesis through M-CSF receptor shedding by up-regulation of TNF-α converting enzyme (TACE). Blood 114, 4517–452 (2009).10.1182/blood-2009-04-215020 ↗
33. Helft, J. et al. GM-CSF mouse bone marrow cultures comprise a heterogeneous population of CD11c+MHCII+ macrophages and dendritic cells. Immunity 42, 1197–1211 (2015).10.1016/j.immuni.2015.05.018 ↗
34. Mitroulis, I. et al. Modulation of myelopoiesis progenitors is an integral component of trained immunity. Cell 172, 147–161.e112 (2018).10.1016/j.cell.2017.11.034 ↗
35. Bono, C. et al. GM-CSF programs hematopoietic stem and progenitor cells during candida albicans vaccination for protection against reinfection. Front Immunol. 12, 790309 (2021).10.3389/fimmu.2021.790309 ↗
36. Shi, Y. et al. Granulocyte-macrophage colony-stimulating factor (GM-CSF) and T-cell responses: what we do and don’t know. Cell Res. 16, 126–133 (2006).10.1038/sj.cr.7310017 ↗
37. Low, S. A. & Kopeček, J. Targeting polymer therapeutics to bone. Adv. Drug Deliv. Rev. 64, 1189–1204 (2012).10.1016/j.addr.2012.01.012 ↗
38. Liu, S. et al. NK cell-based cancer immunotherapy: from basic biology to clinical development. J. Hematol. Oncol. 14, 7 (2021).10.1186/s13045-020-01014-w ↗
39. Lamb, M. G., Rangarajan, H. G., Tullius, B. P. & Lee, D. A. Natural killer cell therapy for hematologic malignancies: successes, challenges, and the future. Stem Cell Res. Ther. 12, 211 (2021).10.1186/s13287-021-02277-x ↗
40. Colomar-Carando, N. et al. Exploiting natural killer cell engagers to control pediatric B-cell precursor acute lymphoblastic leukemia. Cancer Immunol. Res 10, 291–302 (2022).10.1158/2326-6066.CIR-21-0843 ↗
41. Kannan, G. S., Aquino-Lopez, A. & Lee, D. A. Natural killer cells in malignant hematology: a primer for the non-immunologist. Blood Rev. 31, 1–10 (2017).10.1016/j.blre.2016.08.007 ↗
42. Shafat, M. S. et al. Leukemic blasts program bone marrow adipocytes to generate a protumoral microenvironment. Blood 129, 1320–1332 (2017).10.1182/blood-2016-08-734798 ↗
43. Saylor, P. J. et al. Bone health and bone-targeted therapies for prostate cancer: ASCO endorsement of a cancer care Ontario guideline. J. Clin. Oncol. 38, 1736–1743 (2020).10.1200/JCO.19.03148 ↗
44. Shah, N. J. et al. A biomaterial-based vaccine eliciting durable tumour-specific responses against acute myeloid leukaemia. Nat. Biomed. Eng. 4, 40–51 (2020).10.1038/s41551-019-0503-3 ↗
45. Kumar, B. et al. Acute myeloid leukemia transforms the bone marrow niche into a leukemia-permissive microenvironment through exosome secretion. Leukemia 32, 575–587 (2018).10.1038/leu.2017.259 ↗
46. Vasanthakumar, A. et al. Brca1 deficiency causes bone marrow failure and spontaneous hematologic malignancies in mice. Blood 127, 310–313 (2016).10.1182/blood-2015-03-635599 ↗
47. Yan, W.-L., Wu, C.-C., Shen, K.-Y. & Liu, S.-J. Activation of GM-CSF and TLR2 signaling synergistically enhances antigen-specific antitumor immunity and modulates the tumor microenvironment. J. Immunother. Cancer 9, e002758 (2021).10.1136/jitc-2021-002758 ↗
48. Na, Y. R., Jung, D., Gu, G. J. & Seok, S. H. GM-CSF grown bone marrow derived cells are composed of phenotypically different dendritic cells and macrophages. Mol. Cells 39, 734–741 (2016).10.1016/molcells.2016.0160 ↗
49. Robinson, M. J. et al. Long-lived plasma cells accumulate in the bone marrow at a constant rate from early in an immune response. Sci. Immunol. 7, eabm8389 (2022).
50. Hu, Q. et al. Conjugation of haematopoietic stem cells and platelets decorated with anti-PD-1 antibodies augments anti-leukaemia efficacy. Nat. Biomed. Eng. 2, 831–840 (2018).10.1038/s41551-018-0310-2 ↗
51. Tang, P. M. et al. Smad3 promotes cancer progression by inhibiting E4BP4-mediated NK cell development. Nat. Commun. 8, 14677 (2017).
52. Bachurski, D. et al. Extracellular vesicle measurements with nanoparticle tracking analysis – an accuracy and repeatability comparison between NanoSight NS300 and ZetaView. J Extracell. Vesicles 8, 1596016 (2019).10.1080/20013078.2019.1596016 ↗
53. Li, P. et al. Synergistic ferroptosis and macrophage re-polarization using engineering exosome-mimic M1 nanovesicles for cancer metastasis suppression. Chem. Eng. J. 409, 128217 (2021).10.1016/j.cej.2020.128217 ↗
54. Rajendran, S. et al. IL-17 is expressed on beta and alpha cells of donors with type 1 and type 2 diabetes. J Autoimmun. 123, 102708 (2021).10.1016/j.jaut.2021.102708 ↗
55. Gutowski, M. B., Wilson, L., Van Gelder, R. N. & Pepple, K. L. In vivo bioluminescence imaging for longitudinal monitoring of inflammation in animal models of uveitis. Invest. Ophthalmol. Vis. Sci. 58, 1521–1528 (2017).10.1167/iovs.16-20824 ↗
56. Dai, Z. et al. Gender dimorphism in hepatocarcinogenesis-DNA methylation modification regulated X-chromosome inactivation escape molecule XIST. Clin. Transl. Med. 13, e1518 (2023).10.1002/ctm2.1518 ↗
57. Zhang, Y. et al. A bispecific nanosystem activates endogenous NK cells in the bone marrow for hematologic malignancies therapy. figshare https://doi.org/10.6084/m9.figshare.25663173 (2024).10.6084/m9.figshare.25663173 ↗